BlinkLab (ASX:BB1) said the North Shore Pediatric Therapy joined its US clinical study, and it is expected to enroll patients in the coming weeks, according to a Monday Australian bourse filing.

As part of the US registrational study, North Shore's use of the ADOS-2 diagnostic tool will serve as a critical benchmark for standard-of-care comparisons, the filing said.

North Shore, a provider of pediatric services, specializing in the evaluation and treatment of autism, is the second US-based site to join the 100-patient initial phase of the registrational study.

The clinic also provides access to a diverse population of children throughout the Chicago area, ensuring the study reflects a broad range of backgrounds and developmental profiles.

The firm's shares rose 8% on market close on Monday.